Ksilink wishes you all the best for 2022!

Ksilink wishes you all the best for 2022!

What you see here is neither a virtual firework nor has Ksilink become an expressionist. We took this beautiful picture, figuring the AI-based analysis of the pharmacological validation of one of our disease models, to wish you all the best for the coming year. In...
New solutions to treat Rubinstein-Taybi

New solutions to treat Rubinstein-Taybi

Ksilink was happy to welcome the team of Prof. Valérie Mezger-Lallemand from Université Diderot to initiate a collaboration with the aim to establish a new patient-based disease model to identify novel treatment options for patients suffering from Rubinstein-Taybi....